Comprehensive treatment of rectal cancer
DOI:
https://doi.org/10.32782/2415-8127.2022.66.4Keywords:
neoadjuvant chemoradiotherapy, tumor process, rectal cancer, recurrence-free survival, localregional recurrences, quality of life.Abstract
Introduction. Malignant neoplasms of the rectum belong to the group leading in prevalence and mortality among oncological diseases. In 2018, about 1.8 million new cases of colorectal cancer were registered in the world. A favorable outcome of the treatment of patients with rectal cancer in the early stages is not a difficult task, as it is easily solved thanks to only surgical intervention. The biggest problem is the treatment of patients with late-stage (III and IV) rectal cancer. The review of the literature based on the data of randomized studies by various authors highlighted the features of complex treatment of rectal cancer. Aim. To conduct a multicenter analysis of the results of complex treatment of rectal cancer and its effect on the frequency of recurrence and five-year survival. Results. Complete or partial clinical response of the tumor to neoadjuvant therapy is a favorable factor that correlates with an increase in the overall and recurrence-free survival of patients with locally advanced rectal cancer. Achieving such a response may allow some of the unresectable tumors to be converted into a resectable state. Preoperative chemoradiotherapy can affect both the volume of viable tumor mass in the wall of the rectum and affected lymph nodes, including causing its complete elimination. Such regression of the tumor with a decrease in the assessment of T and N categories compared to the preoperative ones is used to evaluate the clinical response. Conclusions. It was established that a prolonged course of neoadjuvant chemoradiation therapy for patients with locally advanced rectal cancer statistically significantly increases the loco-regional control indicators. In addition, tumor downstaging can lead to a complete clinical response. These situations can be observed in 10–30% of patients and can be classified as stage 0 of the disease.
References
Smith FM, Waldron D, Winter DC. Rectum-conserving surgery in the era of chemoradiotherapy. Journal of British Surgery. 2010 Dec;97(12):1752-64.
Habr-Gama A, Perez RO, Nadalin W, Sabbaga J, Ribeiro Jr U, e Sousa Jr AH, Campos FG, Kiss DR, Gama-Rodrigues J. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Annals of surgery. 2004 Oct;240(4):711.
Beets-Tan RG, Leijtens J, Beets GL. Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. Clin Oncol. 2011;29:4633-4640.
Habr-Gama A, Perez RO, Wynn G, Marks J, Kessler H, Gama-Rodrigues J. Complete clinical response after neoadjuvant chemoradiation therapy for distal rectal cancer: characterization of clinical and endoscopic findings for standardization. Diseases of the colon & rectum. 2010 Dec 1;53(12):1692-8.
Habr-Gama A, Perez RO, Proscurshim I, Campos FG, Nadalin W, Kiss D, Gama-Rodrigues J. Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy. Journal of gastrointestinal surgery. 2006 Oct;10(10):1319-29.
Bosset JF, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, Daban A, Bardet E, Beny A, Briffaux A, Collette L. Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results—EORTC 22921. Journal of clinical oncology. 2005 Aug 20;23(24):5620-7.
Gérard JP, Conroy T, Bonnetain F, Bouché O, Chapet O, Closon-Dejardin MT, Untereiner M, Leduc B, Francois É, Maurel J, Seitz JF. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. Journal of clinical oncology. 2006 Oct 1;24(28):4620-5.
Roh MS, Colangelo LH, O’Connell MJ, Yothers G, Deutsch M, Allegra CJ, Kahlenberg MS, Baez-Diaz L, Ursiny CS, Petrelli NJ, Wolmark N. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. Journal of clinical oncology. 2009 Nov 11;27(31):5124.
Bujko K, Wyrwicz L, Rutkowski A, Malinowska M, Pietrzak L, Kryński J, Michalski W, Olędzki J, Kuśnierz J, Zając L, Bednarczyk M. Long-course oxaliplatin-based preoperative chemoradiation versus 5× 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study. Annals of oncology. 2016 May 1;27(5):834-42.
Rubbia-Brandt L, Giostra E, Brezault C, Roth AD, Andres A, Audard V, Sartoretti P, Dousset B, Majno PE, Soubrane O, Chaussade S. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Annals of oncology. 2007 Feb 1;18(2):299-304.
Hofheinz RD, Wenz F, Post S, Matzdorff A, Laechelt S, Hartmann JT, Müller L, Link H, Moehler M, Kettner E, Fritz E. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, noninferiority, phase 3 trial. The lancet oncology. 2012 Jun 1;13(6):579-88.
Lee SU, Kim DY, Kim SY, Baek JY, Chang HJ, Kim MJ, Kim TH, Park JW, Oh JH. Comparison of two preoperative chemoradiotherapy regimens for locally advanced rectal cancer: capecitabine alone versus capecitabine plus irinotecan. Radiation Oncology. 2013 Dec;8(1):1-7.
Jiao D, Zhang R, Gong Z, Liu F, Chen Y, Yu Q, Sun L, Duan H, Zhu S, Liu F, Wang J. Fluorouracil-based preoperative chemoradiotherapy with or without oxaliplatin for stage II/III rectal cancer: a 3-year follow-up study. Chinese Journal of Cancer Research. 2015 Dec;27(6):588. 14. Golo D, But-Hadzic J, Anderluh F, Brecelj E, Edhemovic I, Jeromen A, Omejc M, Oblak I, Secerov-Ermenc A, Velenik V. Induction chemotherapy, chemoradiotherapy and consolidation chemotherapy in preoperative treatment of rectal cancerlong- term results of phase II OIGIT-01 Trial. Radiology and oncology. 2018 Sep 1;52(3):267-74.
Bahadoer RR, Dijkstra EA, van Etten B, Marijnen CA, Putter H, Kranenbarg EM, Roodvoets AG, Nagtegaal ID, Beets- Tan RG, Blomqvist LK, Fokstuen T. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. The Lancet Oncology. 2021 Jan 1;22(1):29-42.
Simson DK, Mitra S, Ahlawat P, Saxena U, Sharma MK, Rawat S, Singh H, Bansal B, Sripathi LK, Tanwar A. Prospective study of neoadjuvant chemoradiotherapy using intensity-modulated radiotherapy and 5 fluorouracil for locally advanced rectal cancer–toxicities and response assessment. Cancer Management and Research. 2018;10:519.
Fernández-Martos C, Pericay C, Aparicio J, Salud A, Safont M, Massuti B, Vera R, Escudero P, Maurel J, Marcuello E, Mengual JL. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging–defined, locally advanced rectal cancer: grupo cáncer de recto 3 study. Journal of Clinical Oncology. 2010 Feb 10;28(5):859-65.
Glynne-Jones R, Counsell N, Quirke P, Mortensen N, Maraveyas A, Meadows HM, Ledermann J, Sebag-Montefiore D. Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control. Annals of oncology. 2014 Jul 1;25(7):1356-62.
Liu SX, Zhou ZR, Chen LX, Yang YJ, Hu ZD, Zhang TS. Short-course versus long-course preoperative radiotherapy plus delayed surgery in the treatment of rectal cancer: a meta-analysis. Asian Pacific Journal of Cancer Prevention. 2015;16(14):5755-62.
Zhou ZR, Liu SX, Zhang TS, Chen LX, Xia J, Hu ZD, Li B. Short-course preoperative radiotherapy with immediate surgery versus long-course chemoradiation with delayed surgery in the treatment of rectal cancer: a systematic review and metaanalysis. Surgical oncology. 2014 Dec 1;23(4):211-21.
Van der Valk MJ, Hilling DE, Bastiaannet E, Kranenbarg EM, Beets GL, Figueiredo NL, Habr-Gama A, Perez RO, Renehan AG, van de Velde CJ, Ahlberg M. Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study. The Lancet. 2018 Jun 23;391(10139):2537-45.
